32 k pneumoniae Search Results


n d 32 k pneumoniae  (ATCC)
99
ATCC n d 32 k pneumoniae
N D 32 K Pneumoniae, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/32+k+pneumoniae/Klebsiella+pneumoniae+subsp%2E+pneumoniae+(Schroeter)+Trevisan/pmc03381897-97-56-61
Average 99 stars, based on 1 article reviews
n d 32 k pneumoniae - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
32 k pneumoniae  (ATCC)
95
ATCC 32 k pneumoniae
Clinical data, RAPD patterns, PFGE types, plasmid fingerprints, IEF of β-lactamases, and ESBLs identified in klebsiella isolates and E. coli transconjugants
32 K Pneumoniae, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/32+k+pneumoniae/16%2F32/pmc00089903-248-215-258
Average 95 stars, based on 1 article reviews
32 k pneumoniae - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
s aureus  (ATCC)
99
ATCC s aureus
Clinical data, RAPD patterns, PFGE types, plasmid fingerprints, IEF of β-lactamases, and ESBLs identified in klebsiella isolates and E. coli transconjugants
S Aureus, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/32+k+pneumoniae/Klebsiella+pneumoniae%3B+subsp%2E+pneumoniae/pm31016969-44-29-40
Average 99 stars, based on 1 article reviews
s aureus - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

Image Search Results


Clinical data, RAPD patterns, PFGE types, plasmid fingerprints, IEF of β-lactamases, and ESBLs identified in klebsiella isolates and E. coli transconjugants

Journal:

Article Title: A Novel Complex Mutant ?-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum ?-Lactamase-Producing Klebsiellae

doi:

Figure Lengend Snippet: Clinical data, RAPD patterns, PFGE types, plasmid fingerprints, IEF of β-lactamases, and ESBLs identified in klebsiella isolates and E. coli transconjugants

Article Snippet: Susceptibility patterns of transconjugants correlated with the data obtained for the corresponding clinical isolates. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain (PFGE type, pI of ESBL) No. of isolates MIC(s) (μg/ml) or range of MICs AMP a PIP PIP-TAZ CTX CTX-CLAV CAZ CAZ-CLAV ATM ATM-CLAV FOX IPM AK GN K. pneumoniae (a, 5.7) 1 >512 >512 >512 32 8 256 128 256 64 32 0.25 2 128 K. pneumoniae (a, 6.0) 8 >512 >512 2–4 8–16 ≤0.03–0.06 128 0.25–0.5 128 0.125 2–4 0.125 1–2 32, 128 K. pneumoniae (d, 6.0) 3 >512 >512 32 16 0.125–0.25 128 1 256 0.25 8 0.125 1 32 K. pneumoniae (b2, 6.0) 2 >512 >512 4–8 16 0.06–0.125 64–128 0.5–1 128–256 0.125–0.25 4–8 0.125 1 32–64 K. pneumoniae (b2, 8.2) 1 >512 128 4 8 0.125 128 0.5 256 0.125 4 0.125 16 4 K. pneumoniae (b1, 8.2) 5 >512 256 4–8 8–16 0.125–0.25 128 0.5–1 256 0.125–0.25 4–8 0.125 8–16 4–8 K. pneumoniae (c, 8.2) 2 >512 256 16 8 0.25 128–256 0.5–1 256–512 0.125 16 0.125–0.25 8 4 K. oxytoca (8.2) 2 512–>512 64 0.5–1 1–2 ≤0.03 8 0.125 8–16 ≤0.03 1 0.125 16 4–8 K. pneumoniae R + b (6.0) 11 >512 64–128 0.5 2–4 ≤0.03 8 0.06–0.125 8–16 ≤0.03 1–2 0.125 0.5 16–32 K. pneumoniae , K. oxytoca R + (8.2) 7 256 16–32 0.5 1 ≤0.03 8 0.125 16 ≤0.03 1–2 0.125 4–8 2 E. coli A15 R − 2 ≤0.5 ≤0.5 ≤0.03 ≤0.03 0.125 0.125 0.06 ≤0.03 1 0.125 0.5 0.25 E. coli ATCC 25922 4 2 2 0.06 ≤0.03 0.25 0.125 0.06 0.06 4 0.125 1 0.5 Open in a separate window a AMP, ampicillin; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; FOX, cefoxitin; IPM, imipenem; TAZ, tazobactam (4 μg/ml); CLAV, clavulanate (2 μg/ml); AK, amikacin; GN, gentamicin. b R + , transconjugants.

Techniques: Plasmid Preparation, Isolation, Bioassay, Sequencing

Antimicrobial susceptibilities of clinical isolates and transconjugants

Journal:

Article Title: A Novel Complex Mutant ?-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum ?-Lactamase-Producing Klebsiellae

doi:

Figure Lengend Snippet: Antimicrobial susceptibilities of clinical isolates and transconjugants

Article Snippet: Susceptibility patterns of transconjugants correlated with the data obtained for the corresponding clinical isolates. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain (PFGE type, pI of ESBL) No. of isolates MIC(s) (μg/ml) or range of MICs AMP a PIP PIP-TAZ CTX CTX-CLAV CAZ CAZ-CLAV ATM ATM-CLAV FOX IPM AK GN K. pneumoniae (a, 5.7) 1 >512 >512 >512 32 8 256 128 256 64 32 0.25 2 128 K. pneumoniae (a, 6.0) 8 >512 >512 2–4 8–16 ≤0.03–0.06 128 0.25–0.5 128 0.125 2–4 0.125 1–2 32, 128 K. pneumoniae (d, 6.0) 3 >512 >512 32 16 0.125–0.25 128 1 256 0.25 8 0.125 1 32 K. pneumoniae (b2, 6.0) 2 >512 >512 4–8 16 0.06–0.125 64–128 0.5–1 128–256 0.125–0.25 4–8 0.125 1 32–64 K. pneumoniae (b2, 8.2) 1 >512 128 4 8 0.125 128 0.5 256 0.125 4 0.125 16 4 K. pneumoniae (b1, 8.2) 5 >512 256 4–8 8–16 0.125–0.25 128 0.5–1 256 0.125–0.25 4–8 0.125 8–16 4–8 K. pneumoniae (c, 8.2) 2 >512 256 16 8 0.25 128–256 0.5–1 256–512 0.125 16 0.125–0.25 8 4 K. oxytoca (8.2) 2 512–>512 64 0.5–1 1–2 ≤0.03 8 0.125 8–16 ≤0.03 1 0.125 16 4–8 K. pneumoniae R + b (6.0) 11 >512 64–128 0.5 2–4 ≤0.03 8 0.06–0.125 8–16 ≤0.03 1–2 0.125 0.5 16–32 K. pneumoniae , K. oxytoca R + (8.2) 7 256 16–32 0.5 1 ≤0.03 8 0.125 16 ≤0.03 1–2 0.125 4–8 2 E. coli A15 R − 2 ≤0.5 ≤0.5 ≤0.03 ≤0.03 0.125 0.125 0.06 ≤0.03 1 0.125 0.5 0.25 E. coli ATCC 25922 4 2 2 0.06 ≤0.03 0.25 0.125 0.06 0.06 4 0.125 1 0.5 Open in a separate window a AMP, ampicillin; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; FOX, cefoxitin; IPM, imipenem; TAZ, tazobactam (4 μg/ml); CLAV, clavulanate (2 μg/ml); AK, amikacin; GN, gentamicin. b R + , transconjugants.

Techniques:

Antimicrobial susceptibilities of clinical isolates and E. coli transformants producing TEM-47 and TEM-68

Journal:

Article Title: A Novel Complex Mutant ?-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum ?-Lactamase-Producing Klebsiellae

doi:

Figure Lengend Snippet: Antimicrobial susceptibilities of clinical isolates and E. coli transformants producing TEM-47 and TEM-68

Article Snippet: Susceptibility patterns of transconjugants correlated with the data obtained for the corresponding clinical isolates. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain (PFGE type, pI of ESBL) No. of isolates MIC(s) (μg/ml) or range of MICs AMP a PIP PIP-TAZ CTX CTX-CLAV CAZ CAZ-CLAV ATM ATM-CLAV FOX IPM AK GN K. pneumoniae (a, 5.7) 1 >512 >512 >512 32 8 256 128 256 64 32 0.25 2 128 K. pneumoniae (a, 6.0) 8 >512 >512 2–4 8–16 ≤0.03–0.06 128 0.25–0.5 128 0.125 2–4 0.125 1–2 32, 128 K. pneumoniae (d, 6.0) 3 >512 >512 32 16 0.125–0.25 128 1 256 0.25 8 0.125 1 32 K. pneumoniae (b2, 6.0) 2 >512 >512 4–8 16 0.06–0.125 64–128 0.5–1 128–256 0.125–0.25 4–8 0.125 1 32–64 K. pneumoniae (b2, 8.2) 1 >512 128 4 8 0.125 128 0.5 256 0.125 4 0.125 16 4 K. pneumoniae (b1, 8.2) 5 >512 256 4–8 8–16 0.125–0.25 128 0.5–1 256 0.125–0.25 4–8 0.125 8–16 4–8 K. pneumoniae (c, 8.2) 2 >512 256 16 8 0.25 128–256 0.5–1 256–512 0.125 16 0.125–0.25 8 4 K. oxytoca (8.2) 2 512–>512 64 0.5–1 1–2 ≤0.03 8 0.125 8–16 ≤0.03 1 0.125 16 4–8 K. pneumoniae R + b (6.0) 11 >512 64–128 0.5 2–4 ≤0.03 8 0.06–0.125 8–16 ≤0.03 1–2 0.125 0.5 16–32 K. pneumoniae , K. oxytoca R + (8.2) 7 256 16–32 0.5 1 ≤0.03 8 0.125 16 ≤0.03 1–2 0.125 4–8 2 E. coli A15 R − 2 ≤0.5 ≤0.5 ≤0.03 ≤0.03 0.125 0.125 0.06 ≤0.03 1 0.125 0.5 0.25 E. coli ATCC 25922 4 2 2 0.06 ≤0.03 0.25 0.125 0.06 0.06 4 0.125 1 0.5 Open in a separate window a AMP, ampicillin; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; FOX, cefoxitin; IPM, imipenem; TAZ, tazobactam (4 μg/ml); CLAV, clavulanate (2 μg/ml); AK, amikacin; GN, gentamicin. b R + , transconjugants.

Techniques:

MICs of piperacillin combined with various concentrations of clavulanate and tazobactam for TEM-47- and TEM-68-producing klebsiella clinical isolates and E. coli transformants

Journal:

Article Title: A Novel Complex Mutant ?-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum ?-Lactamase-Producing Klebsiellae

doi:

Figure Lengend Snippet: MICs of piperacillin combined with various concentrations of clavulanate and tazobactam for TEM-47- and TEM-68-producing klebsiella clinical isolates and E. coli transformants

Article Snippet: Susceptibility patterns of transconjugants correlated with the data obtained for the corresponding clinical isolates. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain (PFGE type, pI of ESBL) No. of isolates MIC(s) (μg/ml) or range of MICs AMP a PIP PIP-TAZ CTX CTX-CLAV CAZ CAZ-CLAV ATM ATM-CLAV FOX IPM AK GN K. pneumoniae (a, 5.7) 1 >512 >512 >512 32 8 256 128 256 64 32 0.25 2 128 K. pneumoniae (a, 6.0) 8 >512 >512 2–4 8–16 ≤0.03–0.06 128 0.25–0.5 128 0.125 2–4 0.125 1–2 32, 128 K. pneumoniae (d, 6.0) 3 >512 >512 32 16 0.125–0.25 128 1 256 0.25 8 0.125 1 32 K. pneumoniae (b2, 6.0) 2 >512 >512 4–8 16 0.06–0.125 64–128 0.5–1 128–256 0.125–0.25 4–8 0.125 1 32–64 K. pneumoniae (b2, 8.2) 1 >512 128 4 8 0.125 128 0.5 256 0.125 4 0.125 16 4 K. pneumoniae (b1, 8.2) 5 >512 256 4–8 8–16 0.125–0.25 128 0.5–1 256 0.125–0.25 4–8 0.125 8–16 4–8 K. pneumoniae (c, 8.2) 2 >512 256 16 8 0.25 128–256 0.5–1 256–512 0.125 16 0.125–0.25 8 4 K. oxytoca (8.2) 2 512–>512 64 0.5–1 1–2 ≤0.03 8 0.125 8–16 ≤0.03 1 0.125 16 4–8 K. pneumoniae R + b (6.0) 11 >512 64–128 0.5 2–4 ≤0.03 8 0.06–0.125 8–16 ≤0.03 1–2 0.125 0.5 16–32 K. pneumoniae , K. oxytoca R + (8.2) 7 256 16–32 0.5 1 ≤0.03 8 0.125 16 ≤0.03 1–2 0.125 4–8 2 E. coli A15 R − 2 ≤0.5 ≤0.5 ≤0.03 ≤0.03 0.125 0.125 0.06 ≤0.03 1 0.125 0.5 0.25 E. coli ATCC 25922 4 2 2 0.06 ≤0.03 0.25 0.125 0.06 0.06 4 0.125 1 0.5 Open in a separate window a AMP, ampicillin; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; FOX, cefoxitin; IPM, imipenem; TAZ, tazobactam (4 μg/ml); CLAV, clavulanate (2 μg/ml); AK, amikacin; GN, gentamicin. b R + , transconjugants.

Techniques: